Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
9 evidence topics · 11 sources
Liver metastases and overall survival in castration-resistant disease
“Men with liver metastases had the worst median OS (13.5 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In summary, men with mCRPC treated with docetaxel who have liver metastases had worse OS duration than men with lung metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 1b landmark radiographic progression-free survival by prior therapy
| Cohort (rinzimetostat 400 mg once daily plus darolutamide) | Landmark rPFS at 3, 4, and 5 months | Median follow-up |
|---|---|---|
| Previously treated with abiraterone | “93%, 84%, and 84% at 3, 4, and 5 months” | “4.9 months” |
| Previously treated with AR inhibitors | “93%, 85%, and 85% at 3, 4, and 5 months” | “4.8 months” |
Phase 1b safety in the broader post-ARPI population
Phase 1b ctDNA responses by androgen receptor genotype and partner agent
Prior androgen receptor pathway inhibitor exposure and outcomes with an ARPI versus cabazitaxel
“Prior ARPI exposure (in 37.7%) predicted inferior outcomes on ARPIs but not on cabazitaxel.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A high baseline ctDNA fraction correlated with reduced rPFS and OS; plasma AR copy number status was not associated with outcomes, but PTEN alterations were linked with shorter OS (hazard ratio: 1.9, multivariable p = 0.02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Duration of response to the first androgen receptor pathway inhibitor
Circulating tumor DNA fraction as a prognostic and predictive factor
“Baseline circulating tumour DNA (ctDNA) fraction above the cohort median and on-treatment ctDNA increase were associated with shorter time to progression (HR = 2.38, P < 0.001; HR = 4.03, P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ctDNA abundance was prognostic independent of clinical features, and holds promise as a stratification biomarker.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes by treatment received before castration resistance
“In the overall population, median TTPD was 12.1 months and trended lower for patients who had received prior ARPi-only treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall median OS was 24.6 months and trended lower for patients who received prior ARPi only or both prior ARPi and taxane.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote